General Information
Revision date
2018-09-07
Product name
AZEDRA (iobenguane I 131) Injection
Product Synonyms
iobenguane I 131
CAS No.
77679-27-7
Icons in SDS
Company Information
company name
Sofie, Co
Section 2
SECTION 2: Hazards identification
Emergency overview: Read package insert prior to use. AZEDRA injection is a diagnostic and therapeutic radiopharmaceutical for intravenous use only. It emits radiation and must be handled with appropriate safety measures to minimize radiation exposure to household contacts consistent with institutional good radiation safety practices and patient management procedures.
Other physicochemical hazards
Rating NFPA: Health – 2 Fire – 0 Specific – Radioactive Stability – 0 HMIS: Health – 2 Flammability – 0 Reactivity/Physical – 0 Personal Protection – Yes
Potential health effects
Inhalation: A small fraction of Iodine-131 may volatilize which may result in asymptomatic physiological uptake by thyroid gland or other tissues. Ingestion: May cause symptomatic physiological uptake by thyroid gland or other tissues. Skin Contact: Can contribute to your overall long-term radiation exposure. Eye Contact: Not considered an acute health hazard but should be avoided since first aid measures are required as described below. Chronic Exposure: The health risks associated with chronic radiation exposure (bone marrow problems and other cancers, thyroid problems, genetic and teratogenic effects) are based on exposures much higher than those permitted occupationally. Aggravation of Pre-existing Conditions: May cause allergic reaction in individuals sensitive to iodine.
